Clinical trial
A Randomized Phase 2/3 Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
NCT07815665 is registered in ClinicalTrials.gov with Summit Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2/3 Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
- Lead sponsor
- Summit Therapeutics
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- September 10, 2026
- Completion date
- December 31, 2030
- Enrollment
- 800 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic urothelial carcinoma, metastatic urothelial carcinoma (uc)